Last $1.95 USD
Change Today -0.01 / -0.51%
Volume 9.9K
MNOV On Other Exchanges
As of 3:18 PM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).

medicinova inc (MNOV) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/14/14 - $5.25
52 Week Low
04/15/14 - $1.66
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MEDICINOVA INC (MNOV)

Related News

No related news articles were found.

medicinova inc (MNOV) Related Businessweek News

No Related Businessweek News Found

medicinova inc (MNOV) Details

MediciNova, Inc., a development stage biopharmaceutical company, focuses on acquiring and developing small molecule therapeutics for the treatment of serious diseases for the United States market. The company’s principal product candidates include MN-166, an ibudilast-based drug candidate, which is in Phase I and Phase II clinical trials for the treatment of drug dependence and pain; and MN-221, a ß2 -adrenergic receptor agonist that has completed Phase II clinical trials for the treatment of acute exacerbations of asthma. It also has other product candidates in the clinical development for the treatment of acute exacerbations of asthma, multiple sclerosis and other central nervous system disorders, bronchial asthma, interstitial cystitis, solid tumor cancers, generalized anxiety disorders/insomnia, preterm labor, urinary incontinence, and thrombotic disorders. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California.

11 Employees
Last Reported Date: 03/27/14
Founded in 2000

medicinova inc (MNOV) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $504.8K
Head of Japanese Office and Vice President
Total Annual Compensation: $293.6K
Chief Medical Officer
Total Annual Compensation: $293.6K
Compensation as of Fiscal Year 2013.

medicinova inc (MNOV) Key Developments

MediciNova Inc. Announces Resignation of David O'Toole as Director

On June 16, 2014, David O'Toole resigned as a director of MediciNova Inc. pursuant to a resolution of the board of directors requiring the resignation of any director not receiving a majority of votes cast as a nominee for election for directors.

MediciNova Inc. Announces Positive Results in Study of MN-001 in Mouse Model of Pulmonary Fibrosis

MediciNova Inc. announced positive results from a study that examined the potential clinical efficacy of MN-001 (tipelukast) for the treatment of pulmonary fibrosis. MN-001, which was administered orally once daily (30, 100 and 300 mg/kg) for 2 weeks, was evaluated in a mouse model of bleomycin-induced pulmonary fibrosis (PF) as measured by CT evaluation of lung density, degree of pulmonary fibrosis using the Ashcroft score based on histopathological staining, and hydroxyproline content, which is an indicator of fibrosis or storage of collagen in tissue. MN-001 significantly decreased (p<0.05) the Ashcroft score compared to Vehicle group after 2 weeks of treatment and MN-001 reduced lung density when compared to the Vehicle-treated group. Moreover, lung hydroxyproline content was significantly reduced compared to the Vehicle group (p<0.01). These results show that treatment with MN-001 has significant anti-fibrogenic effects in bleomycin-induced pulmonary fibrosis in mice. MediciNova previously opened an Investigational New Drug (IND) application with the Division of Pulmonary, Allergy, and Rheumatology Products (DPARP) for MN-001 and will consult with the Division regarding proceeding with Phase 2 clinical development for the treatment of pulmonary fibrosis. MN-001 is a novel, orally bioavailable small molecule compound thought to exert its effects through several mechanisms to produce its anti-inflammatory activity in preclinical models, including leukotriene (LT) receptor antagonism, inhibition of phosphodiesterases (PDE) 3 and 4, and inhibition of 5-lipoxygenase (5-LO). It is postulated that inhibition of the 5-LO pathway exerts anti-inflammatory actions, which has implications in various inflammatory diseases such as arthritis, osteoarthritis, and allergy. Recently, 5-LO has been postulated as a pathogenic factor in fibrotic changes. MN-001's inhibitory effect on 5-LO and the 5-LO/LT pathway is considered to be a novel approach to treat fibrosis. Previously, MediciNova evaluated MN-001 for its potential clinical efficacy in asthma and had positive Phase 2 results. MN-001 has been exposed to more than 600 subjects and considered generally safe and well-tolerated. Bleomycin is an anti-cancer drug used for treatment of different types of malignant tumors. One of the known side effects of bleomycin treatment is pulmonary fibrosis. Bleomycin-induced pulmonary fibrosis in the mouse is widely used as animal model of pulmonary fibrosis.

MediciNova Inc., Annual General Meeting, Jun 13, 2014

MediciNova Inc., Annual General Meeting, Jun 13, 2014., at 15:30 Pacific Standard Time. Location: 4225 Executive Square. Agenda: To elect two Class I directors, as recommended for nomination by the nominating and corporate governance committee and approved by the board, to hold office until the 2017 annual meeting of stockholders and until their successors have been duly elected and qualified, or, if sooner, until their earlier death, resignation or removal; to ratify the audit committee's selection of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2014; and to conduct any other business properly brought before the annual meeting.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MNOV:US $1.95 USD -0.01

MNOV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MNOV.
View Industry Companies

Industry Analysis


Industry Average

Valuation MNOV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.7x
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDICINOVA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at